Lineage Cell Therapeutics Inc at B Riley Fall Growth Biotech Best Ideas (Virtual) Transcript
Hi. So we are welcoming you back to our Fall 2021 Best Idea series. This is the third chapter. My name is Mayank Mamtani. I'm a Senior Biotech Analyst representing the broader healthcare research efforts in trying to bring forward [health] growth ideas within the smid-cap space. This particular one focused within cell therapy. The name of the company is Lineage Cell Therapeutics, ticker LCTX, where I'm pleased to have with me members of the management team: Brian Culley, CEO; Kevin Cook, CFO; Gary Hogge, SVP, Clinical and Medical Affairs; and also very fortunate to be joined by Dr. Jordi Monés, a prominent KOL in the ophthalmology clinical development space. But his particular research is in macular and retinal degeneration. He currently serves as the director in Institut de la Mà cula and a principal investigator with the Barcelona Macula Foundation: Research for Vision.
Thank you, everyone, for joining us. Before we get started, need to make a quick set of disclosures. In the normal course of business, B. Riley Securities seeks to perform
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
